About
Profile
We are a global medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and
Headquarters
Intraday
High
-
Low
-
52-week
High
-
Low
-
MASI
...
Available for logged in users only.
The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.
Contact us via Twitter if you are interested in trying it out.
- Masimo down 6% despite quarterly beats, updated 2024 guidance
- Masimo Non-GAAP EPS of $1.25 beats by $0.30, revenue of $548.9M beats by $3.21M
- Masimo Q4 2023 Earnings Preview
- Masimo Q4 2023 Earnings Preview
- Masimo cut to Hold at Jefferies on valuation
- U.S. appeals court reinstates Apple Watch import ban
- Masimo appoints Bob Chapek to Board of Directors
- Apple to drop blood oxygen feature on watch if appeal fails - reports
- U.S. appeals court affirms tribunal decisions favoring Masimo in Apple patent dispute
- Masimo announces preliminary Q4 consolidated revenue of $541M to $551M
- It's JPM time! Which medtechs are expected to issue updates this week?
- Masimo downgraded at Needham on Apple patent dispute
- Apple mulls long-term software fix for watches while appealing ban - report
- Apple Watch ban paused by appeals court; Apple can sell devices again (update)
- Biggest stock movers today: Tesla, crypto-related names, Cytokinetics, Masimo and more
- Biden has til Sunday to decide on Apple Watch patent dispute. He's watching it.
- Apple mulls software workaround for watches hit by sales curbs - report (update)
- Masimo up 5% on FDA approval of baby monitoring system
- Apple halting Watch sales in compliance with ITC ruling; Biden may still veto
- Apple exec behind iPhone screen, touch ID tech leaving company - report